Twist Bioscience (NASDAQ: TWST) CAO sells shares for tax withholding

Rhea-AI Filing Summary

Twist Bioscience Corp's Chief Accounting Officer, Robert F. Werner, reported an open-market sale of 1,693 shares of common stock. The transaction occurred on February 23, 2026 at an average price of $46.7098 per share.

According to the footnote, these shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units under the company’s equity incentive plans, and the sale was not a discretionary trade by the officer. After this sale, Werner directly holds 55,045 shares of Twist Bioscience common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WERNER ROBERT F.

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		S		1,693(1)	D	$46.7098	55,045	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Robert F. Werner	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Twist Bioscience (TWST) report for Robert F. Werner?

Twist Bioscience reported that Chief Accounting Officer Robert F. Werner sold 1,693 shares of common stock. The sale was executed on February 23, 2026 and was tied to tax withholding obligations from vesting restricted stock units under the company’s equity incentive plans.

How many Twist Bioscience (TWST) shares did the CAO sell and at what price?

Robert F. Werner sold 1,693 shares of Twist Bioscience common stock at an average price of $46.7098 per share. This sale was reported as an open-market transaction and was specifically used to satisfy tax withholding obligations from restricted stock unit vesting.

Was the Twist Bioscience (TWST) insider sale by the CAO a discretionary trade?

No, the sale was not discretionary. The footnote explains that the 1,693 shares were sold to cover tax withholding obligations required by Twist Bioscience’s equity incentive plans, under a mandated “sell to cover” arrangement rather than a voluntary trading decision by the officer.

How many Twist Bioscience (TWST) shares does Robert F. Werner hold after the sale?

After the reported transaction, Robert F. Werner directly holds 55,045 shares of Twist Bioscience common stock. This figure reflects his remaining direct ownership following the 1,693-share sale used to fund tax withholding obligations from restricted stock unit vesting.

What is the role of Robert F. Werner at Twist Bioscience (TWST) in this Form 4 filing?

In this Form 4, Robert F. Werner is identified as Twist Bioscience’s Chief Accounting Officer. His officer status is disclosed alongside the reported sale of 1,693 common shares, which was executed to satisfy tax withholding obligations related to vesting restricted stock units.

What type of security was involved in the Twist Bioscience (TWST) insider transaction?

The transaction involved Twist Bioscience common stock. Robert F. Werner sold 1,693 common shares in an open-market sale at an average price of $46.7098 per share, solely to cover tax withholding obligations stemming from the vesting of restricted stock units.